Associated Papers
Characterizing Longitudinal Molecular Changes in ctDNA in Patients with Metastatic Castration-resistant Prostate Cancer.
Jani CT et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI).
Park JJ et al.
Clinical Genitourinary Cancer, 2026
Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review.
Chanhih N et al.
International Journal of Molecular Sciences, 2025
Nationwide Genomic Data Analysis of Japanese Prostate Cancer Patients From C-CAT Database.
Tsukahara S et al.
Cancer Medicine, 2025
Clinical Context Shapes the Relationship between Genomic Alterations and Response to AR Inhibitors and Chemotherapy in Metastatic Prostate Cancer.
Shah K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration.
Zengin ZB et al.
Prostate Cancer and Prostatic Diseases, 2025
Deep targeted sequencing of circulating tumor DNA to inform treatment in patients with metastatic castration-resistant prostate cancer.
Nørgaard M et al.
Journal of Experimental & Clinical Cancer Research : Cr, 2025
An Autophagy-Targeting Chimera Induces Degradation of Androgen Receptor Mutants and AR-v7 in Castration-Resistant Prostate Cancer.
Bae TH et al.
Cancer Research, 2025
Histopathologic and Molecular Characterization of IDH-Mutant Prostatic Adenocarcinoma.
Samueli B et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 2025
Comparison of androgen receptor mutation detection between plasma extracellular vesicle DNA and cell-free DNA and its relationship to prostate cancer prognosis.
Ding T et al.
Annals of Medicine, 2024
Structural perspectives on the androgen receptor, the elusive shape-shifter.
Johnson MJ et al.
Steroids, 2024
Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project.
Shiota M et al.
Bjc Reports, 2024
Computational investigation of missense somatic mutations in cancer and potential links to pH-dependence and proteostasis.
Sallah S et al.
Plos One, 2024
Prospective clinical sequencing of 1016 Chinese prostate cancer patients: uncovering genomic characterization and race disparity.
Wei Y et al.
Molecular Oncology, 2023
Clinical implications of AR alterations in advanced prostate cancer: A multi-institutional collaboration.
Dorff T et al.
Research Square, 2023
Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease Progression.
Bang S et al.
Cancers, 2023
Androgen receptor mutations modulate activation by 11-oxygenated androgens and glucocorticoids.
Snaterse G et al.
Prostate Cancer and Prostatic Diseases, 2023
Symphony in the crowd: Key genetic alterations in prostate cancer.
Masud N
Cancer Innovation, 2023
A partially open conformation of an androgen receptor ligand-binding domain with drug-resistance mutations.
Doamekpor SK et al.
Acta Crystallographica. Section F, Structural Biology Communications, 2023
Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.
Wang Z et al.
Prostate Cancer and Prostatic Diseases, 2023
Yeast-based evolutionary modeling of androgen receptor mutations and natural selection.
Zhang H et al.
Plos Genetics, 2022
Androgen receptor mutations for precision medicine in prostate cancer.
Shiota M et al.
Endocrine-related Cancer, 2022
Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A et al.
International Journal of Biological Macromolecules, 2022
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.
Herberts C et al.
Nature, 2022
Genomic Profiling of Prostate Cancer: An Updated Review.
Hatano K et al.
The World Journal of Men's Health, 2022
Comprehensive genomic profiling of treatment resistant metastatic castrate sensitive prostate cancer reveals high frequency of potential therapeutic targets.
Kappel C et al.
Clinical Genitourinary Cancer, 2022
Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in Prostate Cancer Patients.
Lieb V et al.
Cells, 2021
Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies.
Jacob A et al.
Cancers, 2021
Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway Inhibition.
Annala M et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients.
Lallous N et al.
Cancers, 2021
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Jayaram A et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology, 2021
Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene?
Mayayo-Peralta I et al.
Endocrine-related Cancer, 2021
Discovery of JNJ-63576253, a Next-Generation Androgen Receptor Antagonist Active Against Wild-Type and Clinically Relevant Ligand Binding Domain Mutations in Metastatic Castration-Resistant Prostate Cancer.
Branch JR et al.
Molecular Cancer Therapeutics, 2021
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians.
Merseburger AS et al.
European Urology, 2021
Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.
Liu M et al.
American Journal of Cancer Research, 2021
Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer.
Fettke H et al.
European Urology, 2020
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
Kohli M et al.
Ebiomedicine, 2020
Comprehensive Analysis of AR Alterations in Circulating Tumor DNA from Patients with Advanced Prostate Cancer.
Ledet EM et al.
The Oncologist, 2020
Evaluation of the genomic alterations in the androgen receptor gene during treatment with high-dose testosterone for metastatic castrate-resistant prostate cancer.
Moses M et al.
Oncotarget, 2020
Towards precision oncology in advanced prostate cancer.
Ku SY et al.
Nature Reviews. Urology, 2019
Identification of single nucleotide variants using position-specific error estimation in deep sequencing data.
Kleftogiannis D et al.
Bmc Medical Genomics, 2019
Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.
Schweizer MT et al.
The Prostate, 2019
TP53 Outperforms Other Androgen Receptor Biomarkers to Predict Abiraterone or Enzalutamide Outcome in Metastatic Castration-Resistant Prostate Cancer.
De Laere B et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2019
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer.
Sumiyoshi T et al.
Scientific Reports, 2019